hypericin has been researched along with Mycosis Fungoides in 1 studies
Mycosis Fungoides: A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, EJ | 1 |
| Mangold, AR | 1 |
| DeSimone, JA | 1 |
| Wong, HK | 1 |
| Seminario-Vidal, L | 1 |
| Guitart, J | 1 |
| Appel, J | 1 |
| Geskin, L | 1 |
| Lain, E | 1 |
| Korman, NJ | 1 |
| Zeitouni, N | 1 |
| Nikbakht, N | 1 |
| Dawes, K | 1 |
| Akilov, O | 1 |
| Carter, J | 1 |
| Shinohara, M | 1 |
| Kuzel, TM | 1 |
| Piette, W | 1 |
| Bhatia, N | 1 |
| Musiek, A | 1 |
| Pariser, D | 1 |
| Kim, YH | 1 |
| Elston, D | 1 |
| Boh, E | 1 |
| Duvic, M | 1 |
| Huen, A | 1 |
| Pacheco, T | 1 |
| Zwerner, JP | 1 |
| Lee, ST | 1 |
| Girardi, M | 1 |
| Querfeld, C | 1 |
| Bohjanen, K | 1 |
| Olsen, E | 1 |
| Wood, GS | 1 |
| Rumage, A | 1 |
| Donini, O | 1 |
| Haulenbeek, A | 1 |
| Schaber, CJ | 1 |
| Straube, R | 1 |
| Pullion, C | 1 |
| Rook, AH | 1 |
| Poligone, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma[NCT02448381] | Phase 3 | 169 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The proportion of patch lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions.~The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described." (NCT02448381)
Timeframe: 16 weeks
| Intervention | lesions with response (Number) |
|---|---|
| SGX301 (Cycle 1 & 2 = SGX301) | 65 |
| Placebo (Cycle 1) | 14 |
"The proportion of plaque lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions.~The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described." (NCT02448381)
Timeframe: 16 weeks
| Intervention | lesions with response (Number) |
|---|---|
| SGX301 (Cycle 1 & 2 = SGX301) | 64 |
| Placebo (Cycle 1) | 7 |
1 trial available for hypericin and Mycosis Fungoides
| Article | Year |
|---|---|
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
Topics: Adult; Anthracenes; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoide | 2022 |